The Inhibition of Human Epithelial Cells Proliferation by Oridoninthrough Interrupted Notch Signalling Pathway

Authors

  • Mingze Xu Author

DOI:

https://doi.org/10.61173/dez3bp87

Keywords:

Oridonin, Epithelial cells, Breast cancer, Notch-1 receptor, Notch signalling pathway

Abstract

Since the Notch signaling pathway plays a vital role in cell proliferation, oridonin restrains cancer cell growth by
limiting the Notch pathway. The study aims to investigate whether oridonin can kill normal epithelial cells similar to
cancer cells in vitro. Also, the study aims to find whether the inhibition of Notch-1 by oridonin is on a transcriptional
level. Methods: The study will use human epithelial cells (MCF10A) and breast cancer cells (MCF7). These two types
of cells will be treated with various concentrations of oridonin (0.01mM, 0.1mM, 1mM, and 10mM) for a different
amount of time (24h, 48h, 72h). The cell viability will be measured by WST-1 assay. Possible Results: There are
eight possible results, three for the proliferation of epithelial cells and two for the transcriptional level of Notch-1 in
epithelial cells. Normal epithelial cells experience a more significant loss of viable cells compared with cancer cells:
(1) with decreased transcription and expression of Notch-1; (2) with decreased expression of Notch-1 but no decrease
in transcription; (3) with a decrease in transcription but no decrease in expression of Notch-1 (4) with no decrease
in expression and transcription of Notch-1. Normal epithelial cells experience a similar or less loss of viable cells
compared with cancer cells, (5) with decreased transcription and expression of Notch-1; (6) with decreased expression
of Notch-1 but no decrease in transcription; (7) with a decrease in transcription but no decrease in expression of Notch-1
(8) with no decrease in expression and transcription of Notch-1. Conclusion: The loss of normal cells is considered a
trade-off for the anti-tumor activity of oridonin. If little or no damage to non-tumorigenic epithelial cells is detected,
then oridonin may be a good cure for breast cancer with fewer side effects. Also, by investigating whether the inhibition
of Notch-1 by oridonin is on a transcriptional level, we can gain more insights into the mechanism of inhibition.

Downloads

Published

2023-06-01

Issue

Section

Articles